Grace Therapeutics, Inc. (GRCE)
GRCE moved a median of +0.28% 30 minutes after news, and 0.00% by the close. How GRCE actually reacts to news — the realized, point-in-time move the market made, measured across 132 labeled events over the last three years with zero look-ahead.
GRCE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 41% | 121 |
| 30-min | +0.28% | 55% | 130 |
| 60-min | 0.00% | 49% | 131 |
| to close | 0.00% | 48% | 124 |
| Middle 50% of GRCE reactions | -0.63% to +1.10% |
|---|---|
| Median reaction (30-min) | +0.28% |
| Measured reactions | 132 |
Half of all Grace Therapeutics, Inc. news events land between -0.63% and +1.10% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when GRCE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GRCE's baseline. Nothing else.
Recent GRCE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Grace Therapeutics, Inc. For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +1.42% | -0.94% | |
| Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference | Press release | GlobeNewswire | -1.39% | -0.47% | |
| Form EFFECT Grace Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.48% | |
| Form S-3 Grace Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +1.15% | +0.92% | |
| Form 10-Q Grace Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.43% | -1.43% | |
| Form 8-K Grace Therapeutics, Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +1.43% | -1.43% | |
| Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update | Press release | GlobeNewswire | +1.43% | -1.43% | |
| Form D Grace Therapeutics, Inc. | SEC filing · Form D | SEC EDGAR | +0.00% | +0.95% | |
| Form 8-K Grace Therapeutics, Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Grace Therapeutics Announces $10 Million Private Placement | Press release | GlobeNewswire | -2.27% | -2.73% | |
| Form 8-K Grace Therapeutics, Inc. For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | -5.04% | -5.46% | |
| Form DEF 14A Grace Therapeutics, Inc. For: Sep 17 | SEC filing · Form DEF | SEC EDGAR | +1.82% | -5.46% | |
| Form DEFA14A Grace Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.82% | -5.46% | |
| Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration | Press release | GlobeNewswire | -5.04% | -5.46% | |
| Form 10-K Grace Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-K | SEC EDGAR | +2.25% | +7.21% | |
| Form 8-K Grace Therapeutics, Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +2.25% | +7.21% | |
| Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update | Press release | GlobeNewswire | +2.25% | +7.21% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.00% | -0.22% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Grace Therapeutics, Inc. (GRCE) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.43% | +0.43% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Grace Therapeutics, Inc. (GRCE) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | — | +0.43% | |
| Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.83% | +0.00% | |
| Form 8-K Grace Therapeutics, Inc. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -0.83% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Grace Therapeutics, Inc. (GRCE) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -1.19% | -5.53% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Grace Therapeutics, Inc. (GRCE) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.00% | +5.28% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.99% | +6.75% | |
| Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.40% | +3.21% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Grace Therapeutics, Inc. (GRCE) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +1.89% | |
| Form 8-K Grace Therapeutics, Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -3.00% | -7.30% | |
| Form 8-K Grace Therapeutics, Inc. For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | -2.06% | +7.55% | |
| Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104 | Press release | GlobeNewswire | — | -45.66% | |
| Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 | Press release | GlobeNewswire | +3.80% | +8.35% | |
| Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences | Press release | GlobeNewswire | -1.57% | -2.01% | |
| Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | +0.60% | -1.69% | |
| Form 10-Q Grace Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.10% | -3.29% | |
| Form 8-K Grace Therapeutics, Inc. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | -1.10% | -3.29% | |
| Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update | Press release | GlobeNewswire | -1.10% | -3.29% | |
| Form 8-K Grace Therapeutics, Inc. For: Jan 10 | SEC filing · Form 8-K | SEC EDGAR | +2.47% | -2.75% | |
| Form 10-Q/A Grace Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.14% | +4.98% | |
| Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference | Press release | GlobeNewswire | +0.00% | -1.96% | |
| Form 10-Q Grace Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.98% | — | |
| Form 8-K Grace Therapeutics, Inc. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +1.98% | — | |
| Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update | Press release | GlobeNewswire | +1.98% | — | |
| Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting | Press release | GlobeNewswire | -0.33% | +0.37% | |
| Form 8-K Grace Therapeutics, Inc. For: Oct 23 | SEC filing · Form 8-K | SEC EDGAR | -0.95% | -0.32% | |
| Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review | Press release | GlobeNewswire | -0.95% | -0.32% | |
| Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting | Press release | GlobeNewswire | +0.00% | -0.32% | |
| Form 8-K Grace Therapeutics, Inc. For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | +0.65% | +0.65% | |
| Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 | Press release | GlobeNewswire | +0.65% | +0.65% | |
| Form 8-K Grace Therapeutics, Inc. For: Sep 12 | SEC filing · Form 8-K | SEC EDGAR | +1.14% | -0.97% | |
| Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | +0.00% | +3.38% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GRCE section they belong to.
Where else GRCE is measured.
GRCE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Grace Therapeutics, Inc.'s median reaction calculated?
Every labeled GRCE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 132 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of GRCE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GRCE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.